We developed a modified double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) that detected relatively low concentrations of known Pneumocystis carinii antigen added to buffer or rat sera. Artificial immunization-derived polyclonal rabbit anti-P. carinii antibody was used on the solid phase to capture the antigen. Infection-derived (after P. carinii pneumonia) polyclonal rat anti-P. carinii antibody or a mixture of five murine monoclonal antibodies was used as the antigen detector antibody. Rabbit anti-rat immunoglobulin G antibody or goat anti-mouse immunoglobulin G antibody conjugated to alkaline phosphatase was used as the final antibody. After standardization and optimization of the various reactants in this ELISA system, approximately 53 ng of known P. carinii antigen per ml suspended in phosphate-buffered saline-Tween 20 buffer or 210 ng of antigen per ml suspended in normal rat serum diluted 1:4 could be detected. In addition, an indirect ELISA for P. carinii antibody measurement was developed, using as the antigen a soluble supernatant from a sonicated preparation of Percoll-purified whole cysts and trophozoites to coat the solid phase. Limited studies with sera from a small number of caesarian-obtained, barrier-sustained rats from Charles River Breeding Laboratories, Inc., and the National Institutes of Health and sera from normal and heavily infected rats indicated that the caesarian-obtained, barrier-sustained rats had negligible levels of antibody. The normal and heavily infected rats had variable antibody titers. A significantly high level of P. carinii antigenemia was detected in only 2 (11%) of 18 heavily infected rats. Extensive studies of the P. carinii pneumonia rat model with the ELISA did not reveal significant serum P. carinii antigenemia during the acute stage of infection. However, soluble P. carinii antigen was detected by the ELISA and Western blot assays in the supernatant of lavage fluid after centrifugation to sediment intact organisms. As expected, P. carinii antigens were detected by these assays in the lavage pellet recovered after centrifugation. In conclusion, the antigen assay used in this study detected P. carinii antigen in lung lavage but failed to detect P. carinii antigen in rat serum during the acute phase of infection.
In recent years, pneumocystosis has been recognized as a serious, life-threatening infection in immunosuppressed hosts. In a detailed epidemiologic study, Walzer et al. (51) found that the highest rates of Pneumocystis carinii pneumonia occurred in patients with leukemia. High rates also occur in patients with lymphomas, primary immune deficiency diseases, and organ transplants (7) and in bone marrow transplant patients (35) . Recent reports (10, 13, 40) emphasize that P. carinii pneumonia has become a significant cause of morbidity and mortality in patients diagnosed with the acquired immune deficiency syndrome.
At present, the most reliable and sensitive diagnostic procedure for P. carinii pneumonia involves (38, 41) and enzyme-linked immunosorbent assays (ELISAs) (32) as a diagnostic or prognostic tool has not proven of great value.
The detection of circulating antigens is of diagnostic value in certain fungal (34) , bacterial (28, 47) , Toxoplasma (2, 3, 6, 9, 25, 50) , Schistosoma (1, 14, 15, 26, 37) , filarial (16, 21, 23, 39) , and Toxocara (4) infections. P. carinii antigenemia has been reported by Pifer and co-workers in P. carinii pneumo-* Corresponding author. nia patients by using counterimmunoelectrophoretic (CIE) techniques (35, 41, 45, 46) and by using a latex agglutination test (27, 43) . One worker reported limited success detecting P. carinii antigenemia in a few human sera with ELISA technology (48) . However, other workers have not confirmed the value of these antigenemia assays, especially the CIE assay, for detecting antigenemia in human sera (22, 33, 49) .
Considering the potential importance of an antigenemia assay for P. carinii pneumonia, we decided to investigate P. carinii antigenemia in a rat model system. We chose this system so that the induction of P. carinii pneumonia could be controlled and defined. This avoids the uncontrolled and unknown factors associated with human P. carinii pneumonia. In addition, Pifer et al. (42) have reported antigenemia in rats, indicating that, in her laboratory, antigenemia in rats can be detected by CIE. Thus, the rat model system is the best available for controlled antigenemia studies. We chose to use an ELISA since it is potentially 10 times more sensitive than CIE (12) and lends itself well in terms of quantitation, technical ease, and reproducibility. We developed antigen detector ELISAs that detected relatively small amounts of known P. carinii antigen and utilized these assays to test sera from rats for antigenemia during development of steroid-induced P. carinii pneumonia, during recovery and during a second cycle of steroid-induced pneumonia followed by recovery. ELISAs were also developed to follow antibody responses in these animals.
MATERIALS AND METHODS
Source of rats. Unless otherwise indicated, the rats used in this study were Sprague-Dawley male rats obtained from Sasco, Omaha, Nebr. In one base-line antigenemia-antibody study, two additional sources of Sprague-Dawley rats were used. Caesarian-obtained, barrier-sustained, and virus-antibody-free (COBS/VAF) rats were purchased from Charles River Breeding Laboratories, Inc., Wilmington, Mass. COBS rats were also obtained from the National Institutes of Health (NIH).
Preparation of antigen. A soluble P. carinii antigen preparation, obtained by centrifugation of a sonicated mixture of Percoll-purified whole cysts and trophozoites, was used in the ELISA. To obtain the soluble antigen, minced rat lung from immunosuppressed rats was digested as described by Walzer et al. (53) , with some modifications (17) . Digestion was carried out in a solution of collagenase, hyaluronidase, DNase, and Hanks balanced salt solution, followed by a series of washes to remove the enzymes. Control antigen from normal rat lung (NRL) was prepared in a similar manner, except that the preparation was not fractionated on a Percoll gradient because too little protein was recovered when this was done. The NRL preparation often contained 104 to 106 cysts per g of lung, whereas the soluble antigen preparation was derived from immunosuppressed rats and contained 108 to 109 cysts per g of lung. Trophozoite counts usually were 10-fold higher than cyst counts in the soluble antigen preparations. Cyst and trophozoite counts were done on toluidine blue O-and Giemsa-stained preparations, respectively, as described previously (11, 24) .
The lavage source of whole cysts and trophozoites was prepared as previously described (18) . This antigenic preparation was used in the Western blotting (immunoblotting) procedures. Lavage specimens were also obtained in a similar manner from selected animals being monitored for serum antigenemia.
Protein assays were performed as previously described (5) .
Preparation of antisera. Rabbit serum was obtained from four male New Zealand White rabbits immunized with the percoll-purified mixture of whole trophozoites and cysts.
Preimmune serum also was collected from these rabbits and stored at -20°C. Each rabbit was immunized subcutaneously with 5 x 108 whole cysts and trophozoites (not subjected to sonication) emulsified in incomplete Freund adjuvant and boosted 2 weeks later with the same immunogen. A final immunogen boost was given at 4 weeks without the adjuvant. Sera were collected 3 days after the final boost. The immunization-derived rabbit serum was fractionated into the gamma globulin-rich fraction by ammonium sulfate precipitation (8) large-scale rat study, serum was collected weekly from rats undergoing various regimens of immunosuppression and recovery from immunosuppression. These sera were stored at -20°C until tested.
ELISA for antibody and antigen. The indirect ELISA for antibody determinations was performed as described previously (18) . The modified double-antibody sandwich (MDAS) ELISA for antigen detection was performed with reagents, buffers, and amounts identical to those used for the indirect ELISA (18) . The only modifications included the coating of rabbit gamma globulin (capture antibody) on the solid phase instead of soluble P. carinii digest or NRL antigen. The sample to be assayed for P. carinii antigen was added and incubated for 2 h at 25°C. The plates were shaken dry, washed four times with phosphate-buffered saline (PBS)-Tween 20 buffer and shaken dry again. The detector antibody was either polyclonal infection-derived rat serum or a mixture of five murine monoclonal antibodies (MAbs) (18) . Detector antibody was diluted in PBS-Tween 20 buffer, added to each well in a 50-1jl volume, and incubated at room temperature in a humid chamber for 2 h. The plates were shaken dry and washed four times in PBS-Tween 20 before the addition of the conjugated antibody against rat or mouse immunoglobulin. Negative control wells included (i) coating buffer instead of rabbit gamma globulin, (ii) PBS-Tween 20 instead of antigen, (iii) PBS-Tween 20 instead of detector antibody, (iv) PBS-Tween 20 instead of conjugated antibody, and (v) normal rat serum instead of detector antibody. These negative control wells were distributed throughout the plates to give the maximum number of negative controls on each plate. Each sample was measured in duplicate, and the zero equilibration for reading absorbance on test samples MAbs and post-P. carinii pneumonia rat sera (positive controls) are shown in Fig. 3 . The sensitivity of the pooled MAbs as the detector antibody when the soluble P. carinui digest was diluted in PBS-Tween 20 buffer was similar to that obtained with the infection-derived sera. However, at higher concentrations of soluble digest the MAb detector mixture was considerably more reactive than the polyclonal rat infection-derived serum.
Base-line antibody and antigenemia measurements. Preliminary experiments were carried out to determine the baseline reactivity of the antibody and antigenemia assays in individual rats. The antibody levels, as measured by the indirect ELISA on 18 male Sprague-Dawley caesarian-obtained, barrier-sustained (COBS/VAF Plus), COBS (NIH) Sprague-Dawley, 18 normal male Sprague-Dawley, and 18 heavily infected male Sprague-Dawley rats (week 9 of immunosuppression), are shown in' Fig. 4 . Antigenemia levels of these four groups of rats are shown in Fig. 5 shown in Fig. 6 . These data represent the mean absorbance in the MDAS ELISA measuring antigenemia in a 1:4 dilution of serum with infection-derived rat serum as the detector antibody. The absorbance levels dropped during both immunosuppression periods and rose during both recovery periods. A similar pattern but with lower absorbance values was seen with the pooled MAb detector system to measure antigenemia in a 1:4 dilution of serum (Fig. 7) . Surprisingly, the control rats exhibited a marked rise in absorbance values in serum samples assayed 15 weeks into the study.
The mean reciprocal IgG antibody titers to the soluble P. carinii antigen of the control and test rats are shown in Fig.  8 . The mean antibody titer of the control rats rose steadily over the entire time course of the large-scale rat study. The titers of the test rats tended to remain lower during immunosuppression, followed by a rise in antibody titer during recovery periods. IgM levels (data not shown) remained at the -1:50 level throughout the study.
Because the pilot study results suggested the likelihood that no serum antigenemia would be detected, lavage specimens were collected for the antigenemia assay from two rats 108 to 109 cysts per g of lung. Thus the assay failed to detect consistently significant antigenemia in sera taken from rats at the peak of immunosuppression (9 weeks). A pilot study conducted before the large-scale rat study also did not reveal antigenemia during various phases of acute disease induction. HIowever, we found antigenemia levels rose after recovery. In this study the antigenemia assays were done on sera from six rats before immunosuppression, during 9 weeks of immunosuppression and during 9 weeks of recovery from immunosuppression. Six control rats were also included as part of the pilot study. The immunosuppression and recovery regimens and sera collection schedules were identical to those described above for the large-scale rat study in Materials and Methods. Since the pilot and large-scale studies gave similar results, only the more extensive large-scale rat study data are described below.
Large-scale rat study. The protocol used in the large-scale study is described in Materials and Methods and illustrated in Fig. 1 . Serum was collected for antigenemia and antibody assays, as indicated. Rats in groups 1, 2, and 3 lost weight during bouts of immunosuppression and gained weight during recovery periods. The group 4 control rats increased steadily in mean body weight from 240 to 450 g.
The antigenemia patterns of the four groups of rats are each before immunosuppression, after 2, 4, and 6 weeks of the initial suppression, after 9 weeks of recovery, after the second (4 weeks) immunosuppression, and after the final 9 weeks of recovery in the large-scale study. Control animal lavages were also done at intervals throughout the study. Light lavage specimens were centrifuged (10,000 x g for 15 min), a portion of the resulting pellet was stained, and the number of cysts was determined (Fig. 1) Histological studies (Gormori silver and hematoxylin and eosin stains) revealed no detectable pathology due to P. carinii in rats before the study. After 2 weeks of treatment, group 1 rats showed minor lung changes. After 4 weeks of immunosuppression, group 2 rats showed significant alveolar honeycomb formation with some cysts. Group 3 rats, after 6 weeks of immunosuppression, showed many cysts and significant honeycomb formation. At the end of each recovery period, each group showed no evidence of prior P. carinii pneumonia. The control rats at each sampling period showed no evidence of P. carinii pneumonia as measured histologically.
The antigen detection ELISA, with pooled MAbs as the detector, revealed significant absorbance activity in lavage specimens collected during the acute phase of P. carinii infection. Fresh lavage specimens were centrifuged at high speed (10,000 x g for 15 min) to sediment all trophozoites and cysts. Antigen could be detected by the MDAS ELISA with pooled MAbs as the detector in the lavage supernatant (free of P. carinii organisms) and in the pellet that contained the intact organisms. The antigen activity was still present in the pellet after it was washed to remove vestiges of supernant. These data strongly suggested that P. carinii antigen A and B, conjugate controls for lavage supernant and pellet, respectively, from immunosuppressed rats; C and C, lavage supernatant and pellet, respectively, from control rats; E, lavage supernatant from test rats; F, lavage pellet from test rats; G, whole P. carinii digest; C, D, E, F, and G, pooled MAbs and conjugate.
could be detected in the lavage specimen either as soluble antigen or in the whole organisms. However, there was considerable variability in absorbance values (antigenemia) from different rats, and no correlation could be made between length of immunosuppression or number of cysts and the absorbance value. In retrospect we believe the light lavage resulted in considerable variability in the quality of the samples recovered from the lungs. Also the focus on monitoring by cyst counts ignored the likely changes in trophozoite populations during immunosuppression and recovery phases.
To confirm the presence of antigen in the lavage supernatant and pellet, lavage collected from three additional rats immunosuppressed for 6 weeks were analyzed by Western blotting. After centrifugation at 2,000 x g for 10 min, the lavage pellet was washed twice at 2,000 x g for 10 min and suspended in buffer. A portion of the initial supernatant was centrifuged a second time at 10,000 x g for 15 min, and the supernatant was recovered for analysis. Three control rats taken at week 28, a time when no organisms were detected in the lavage (Fig. 1) , were similarly processed. The washed pellet and high-speed centrifuged supernatant from immunosuppressed and control rats were subjected to Western blot analysis as previously described. Pooled MAbs were used as the detector antibody, and comparison was made with whole P. carinii digest antigen, which contains known P. carinhi molecules that have been described and characterized earlier (19) . The lavage supernatant, lavage pellet, and whole P. carinii digest antigens (Fig. 9, lanes E, F, (Fig. 4) . The COBS rat antibody titers were consistently clustered at the negative or nonsignificant level of antibody. However, the COBS rats used were relatively young (2 to 4 weeks old) compared with heavily infected rats (16 weeks old). In the large-scale study the antibody response against P. carinii increased with age (Fig. 8) . We observed some increase in specific anti-P. carinii IgG antibody in the heavily infected rats, but there was considerable overlap between titers of normal and infected rat sera. In unpublished studies, we found that antibody titers tended to remain low during prolonged (8 to 9 weeks) immunosuppression but rose when the animals were allowed to recover for 2 to 3 months. Walzer et al. (52) observed an increase in serum IgG antibody titers with steroid tapering and clearance of the organism from the lungs, but suppression of IgG was observed during induction of P. carinii infection. These results indicate that antibody responses are not reliable indicators of P. carinii pneumonia status. Other workers (31, 32, 38, 41) have made similar conclusions.
The Western blot results of our studies (Fig. 2) showed that the immunization-derived rabbit gamma globulin detected major P. carinii antigenic components also recognized by the infection-derived rat antibody. Absorption studies indicated the rabbit and rat infection-derived antisera against P. carinii contained antibody or antibodies against common epitopes. There were other common antigenic bands detected by the rat infection-and rabbit immunization-derived polyclonal antibodies other than the 116 and 50 to 55-kDa bands. The band at approximately 170 kDa appeared common to the two sources of antibodies. There also appeared to be some minor unique bands. However, these bands were not always present, whereas the 116-and 50-to 55-kDa bands were consistently present. Thus we concluded they were the dominant P. carinii-associated bands (19) .
Based on these characteristics of the rabbit and rat antisera, we chose to use the rabbit antiserum as a capture antigen because it had higher titer against P. carinii; most importantly, we had a sufficient quantity of it to use throughout the study. Also, preliminary studies (unpublished) indicated that when infection-derived rat antibody was used as the capture antibody there was no increase in the sensitivity of the system. We decided to use infection-derived rat antibody against P. carinii as the antigen detector antibody based on the rationale that antibody produced during recovery from clinical P. carinii pneumonia would be relevant to the infection-disease recovery process and that rat sera did not have the anti-rat antibody. When known soluble P.
carinii digest antigen was diluted in PBS-Tween 20 buffer, the system detected as little as 53 ng of antigen per ml (Fig.   3 ). Slightly less (210 ng/ml) sensitivity was achieved when the antigen was placed in 1:4 normal rat serum (Fig. 3) .
Using a much purer antigen preparation, Meckstroth et al. (34) detected 38 ng of Candida albicans antigen per ml of serum. Schistosomajaponicum antigen has been detected at 100-ng/ml concentrations in serum (44) . Other parasitic antigen detection ELISA systems can detect as low as 31 ng of Toxoplasma antigen per ml (9) and 125 ng of Schistosoma antigen per ml (15) . Thus, the sensitivity of our MDAS ELISA approached these values.
The loss of sensitivity that occurred when antigen was placed in serum (Fig. 3) could reflect problems associated with immune complexes or the interfering properties of complement and other serum proteins. Specific interference and steric interference or poor affinity of the detector antibody could reduce sensitivity. Sensitivity problems of these types have been reported by Yolken (54) with ELISAs. In our study, internal controls (described in Materials and Methods) were monitored for the presence of P. cariniiimmune complexes. There was no evidence for an increase in the level of immune complexes at any point in the study.
P. carinii antigenemia has been detected by CIE in humans (35, 41, 46) and rats (42) . Recently Jarowenko et al. (27) reported that a latex particle agglutination test could be used to successfully detect P. carinii antigenemia. However, other workers have reported low sensitivity (33) or failure to detect antigenemia (22, 36) . In our preliminary base-line study (Fig. 5 ) the MDAS ELISA detected antigenemia in only 2 of 18 heavily immunosuppressed rats with obvious P. carinii pneumonia. To clarify these discrepancies we monitored temporally the P. carinii antibody and antigenemia patterns before and during induction and during recovery from steroid-induced P. carinii pneumonia in the rat model with hopes that additional information would be obtained that shed light on the significance of any antigenemia patterns which might occur. A pilot study (data not shown) involving six immunosuppressed and six normal control rats showed no detectable antigenemia during the acute phase of disease, but apparently antigenemia did rise during recovery. The more extensive large-scale study confirmed our pilot study observations that antigenemia was not detectable during acute disease but seemed to rise during recovery periods ( Fig. 6 and 7) . However, the control rats (given no immunosuppression) in the large-scale study also exhibited a rise in antigenemia during the same time period. The fact that antigenemia rose in a similar manner in both experiments suggests that the observation was real. However, except for the similarity in aging and ages of the animals, we have no satisfactory explanation for significance of the observation.
The inability to detect P. carinii antigen in rat serum may be due to a defective test system. However, the ability of the system to detect relatively minute quantities of known P. carinii antigen suggests the test was functional and sensitive. Also, the system detected P. carinii antigens in lavage fluid collected from rats with clinical pneumocystosis (see below).
The absence of P. carinii antigen in rat serum could be due to the inacessibility of this pulmonary pathogen to the bloodstream (sequestered because of the tight adherence of organism to the host type I pneumocytes) or the lack of P. carinii virulence factors in defending against phagocytosis by host monocytes. Recently, other workers (13, 20) reported dissemination of P. carinii to multiple organ systems in humans; this supports the concept of Iymphatic and hematogenous routes of spreading. However, dissemination seems to be a rare event and apparently does not occur regularly. To date, serum antigenemia has been reported primarily in infections where the location of the pathogen in VOL. 26, 1988 on November 6, 2017 by guest http://jcm.asm.org/ Downloaded from the body provides easy access of the pathogen or its antigens to the general circulation.
The MDAS ELISA and Western blot with pooled MAbs as the detector detected P. carinii antigen in the lavage fluid collected during acute P. carinii pneumonia. Antigen also was detected in the pellet recovered after centrifugation. This was not surprising, because P. carinii cysts could also be demonstrated after smears of the pellet sediment were stained with toluidine blue 0. However, the absorbance values (indicator of antigen concentration) were variable and did not correlate well with the number of cysts in the pellet. A number of factors might have contributed to lack of correlation. They include (i) the ability or inability of the organisms to remain tightly bound to capture antibody during subsequent washes in the MDAS ELISA procedure, (ii) significant variability in the trophozoite/cyst ratio, (iii) the possibility of steric hindrance in a system that captures intact organisms, and (iv) the possibility that the organisms or soluble P. carinii digest had already reacted in vivo with host antibody against P. carinii and had fewer reactive epitopes available for reaction with the capture antibody used in the MDAS ELISA. In retrospect, more consistent results may have been obtained if the lavage fluid had been sonicated sufficiently to solubilize the P. carinii before performing the antigenemia assay.
Of great interest was the detection of soluble P. carinii antigen in the lavage supernant fluid after removal of organisms via centrifugation (Fig. 9) . If P. carinii antigens can be demonstrated in lavage fluids that contain few, if any, cysts, then a useful diagnostic tool might be developed for diagnosing pneumocytosis before the acute phase of the disease. Further studies are necessary to confirm the specificities of the banding reactions found at 66 and 90 kDa. Although diagnostic techniques that require invasion of the lung are not desirable, the current controversy about the reliability of serum antigenemia assays demands further exploration of assays that use specimens collected from the lung. Further studies are underway to clarify factors affecting the antigenemia assay and characterize the kinetics of P. carinii antigens in lavage fluid and their relationship to the disease process in rats.
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